• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

    4/16/25 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09
    • First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1
    • Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase
    • Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increase

    ABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025.

    • First-quarter sales increased 4.0 percent on a reported basis, 6.9 percent on an organic basis, or 8.3 percent when excluding COVID-19 testing-related sales.
    • First-quarter GAAP diluted EPS of $0.76 and adjusted diluted EPS of $1.09, which excludes specified items and reflects double-digit growth compared to the prior year.
    • Abbott reaffirms all previously provided full-year 2025 financial guidance.
    • In March, Abbott obtained CE Mark for its Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System through participation in Abbott's PFA clinical studies. The company will further expand the use of Volt in EU markets throughout the second half of the year.
    • In March, Abbott announced the initiation of its U.S. pivotal trial, TECTONIC, to evaluate its investigational Coronary Intravascular Lithotripsy (IVL) System in treating severe calcification in coronary arteries prior to implanting a stent.
    • In March, Abbott presented new two-year data from its TRILUMINATE™ pivotal trial that showed Abbott's TriClip™ device significantly reduced the rate of heart failure-related hospitalizations, while continuing to provide a sustained reduction of tricuspid regurgitation and significant improvements in quality of life.
    • Abbott's two new manufacturing and R&D investments in Illinois and Texas, totaling $0.5 billion, are projected to go live by the end of 2025.

    "Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert B. Ford, chairman and chief executive officer, Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."

    FIRST-QUARTER BUSINESS OVERVIEW

    Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business.

    Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.  

    First Quarter 2025 Results (1Q25)



    Sales 1Q25 ($ in millions)

    Total Company



    Nutrition



    Diagnostics



    Established

    Pharmaceuticals



    Medical Devices

    U.S.

    4,168



    955



    871



    —



    2,339

    International

    6,190



    1,191



    1,183



    1,260



    2,556

    Total reported

    10,358



    2,146



    2,054



    1,260



    4,895

    % Change vs. 1Q24



















    U.S.

    8.4



    8.8



    (6.4)



    n/a



    15.0

    International

    1.2



    0.1



    (7.8)



    2.7



    5.7

    Total reported

    4.0



    3.8



    (7.2)



    2.7



    9.9

    Impact of foreign exchange

    (2.8)



    (2.4)



    (2.3)



    (5.1)



    (2.7)

    Impact of business exit*

    (0.1)



    (0.6)



    —



    —



    —

    Organic

    6.9



    6.8



    (4.9)



    7.8



    12.6





















        U.S.

    8.8



    10.4



    (6.4)



    n/a



    15.0

        International

    5.7



    4.2



    (3.8)



    7.8



    10.5

     

    Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

    *Quarter to date March 31, 2025, reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.

    Total company sales increased 4.0 percent on a reported basis, 6.9 percent on an organic basis, or 8.3 percent when excluding COVID-19 testing-related sales1. 

    Nutrition



    First Quarter 2025 Results (1Q25)



    Sales 1Q25 ($ in millions)

    Total



    Pediatric



    Adult

    U.S.

    955



    588



    367

    International

    1,191



    453



    738

    Total reported

    2,146



    1,041



    1,105













    % Change vs. 1Q24











    U.S.

    8.8



    14.2



    1.1

    International

    0.1



    (8.4)



    6.1

    Total reported

    3.8



    3.2



    4.4

    Impact of foreign exchange

    (2.4)



    (1.7)



    (2.9)

    Impact of business exit*

    (0.6)



    —



    (1.4)

    Organic

    6.8



    4.9



    8.7













        U.S.

    10.4



    14.2



    4.8

        International

    4.2



    (4.8)



    10.6



    *Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.

    Worldwide Nutrition sales increased 3.8 percent on a reported basis and 6.8 percent on an organic basis in the first quarter.

    In Pediatric Nutrition, global sales increased 3.2 percent on a reported basis and 4.9 percent on an organic basis. Sales growth in the U.S. was driven by growth across Abbott's comprehensive portfolio of products designed to meet the unique nutrition needs of infants and children.

    In Adult Nutrition, global sales increased 4.4 percent on a reported basis and 8.7 percent on an organic basis, which was led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes. 

    Diagnostics



    First Quarter 2025 Results (1Q25)



    Sales 1Q25 ($ in millions)

    Total



    Core Laboratory



    Molecular



    Point of Care



    Rapid

    Diagnostics

    U.S.

    871



    332



    40



    100



    399

    International

    1,183



    845



    82



    42



    214

    Total reported

    2,054



    1,177



    122



    142



    613





















    % Change vs. 1Q24



















    U.S.

    (6.4)



    7.1



    (4.4)



    1.5



    (16.9)

    International

    (7.8)



    (5.6)



    (6.7)



    4.4



    (17.9)

    Total reported

    (7.2)



    (2.3)



    (5.9)



    2.4



    (17.3)

    Impact of foreign exchange

    (2.3)



    (3.2)



    (2.4)



    (0.8)



    (1.2)

    Organic

    (4.9)



    0.9



    (3.5)



    3.2



    (16.1)





















        U.S.

    (6.4)



    7.1



    (4.4)



    1.5



    (16.9)

        International

    (3.8)



    (1.3)



    (3.1)



    7.3



    (14.6)

     

    Global Diagnostics sales decreased 7.2 percent on a reported basis, decreased 4.9 percent on an organic basis, or increased 0.5 percent when excluding COVID-19 testing-related sales1.

    Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.

    COVID-19 testing-related sales were $84 million in the quarter, compared to $204 million in the first quarter of the prior year.

    Global Core Laboratory Diagnostics sales decreased 2.3 percent on a reported basis and increased 0.9 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China. 

    Established Pharmaceuticals



    First Quarter 2025 Results (1Q25)



    Sales 1Q25 ($ in millions)

    Total



    Key Emerging

    Markets



    Other

    U.S.

    —



    —



    —

    International

    1,260



    965



    295

    Total reported

    1,260



    965



    295













    % Change vs. 1Q24











    U.S.

    n/a



    n/a



    n/a

    International

    2.7



    4.0



    (1.2)

    Total reported

    2.7



    4.0



    (1.2)

    Impact of foreign exchange

    (5.1)



    (5.3)



    (4.3)

    Organic

    7.8



    9.3



    3.1













        U.S.

    n/a



    n/a



    n/a

        International

    7.8



    9.3



    3.1

     

    Established Pharmaceuticals sales increased 2.7 percent on a reported basis and 7.8 percent on an organic basis in the first quarter.

    Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 4.0 percent on a reported basis and 9.3 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East. 

    Medical Devices



    First Quarter 2025 Results (1Q25)



    Sales 1Q25 ($ in millions)

    Total



    Rhythm

    Management



    Electro-

    physiology



    Heart

    Failure



    Vascular



    Structural

    Heart



    Neuro-

    modulation



    Diabetes

    Care

    U.S.

    2,339



    304



    299



    262



    268



    282



    176



    748

    International

    2,556



    281



    330



    77



    442



    295



    52



    1,079

    Total reported

    4,895



    585



    629



    339



    710



    577



    228



    1,827

































    % Change vs. 1Q24































    U.S.

    15.0



    12.3



    11.1



    10.6



    5.5



    20.9



    (2.8)



    27.1

    International

    5.7



    (3.7)



    4.0



    14.3



    1.6



    4.6



    16.3



    10.1

    Total reported

    9.9



    4.0



    7.3



    11.4



    3.0



    11.9



    1.0



    16.5

    Impact of foreign exchange

    (2.7)



    (2.1)



    (2.6)



    (1.0)



    (2.7)



    (2.8)



    (1.2)



    (3.3)

    Organic

    12.6



    6.1



    9.9



    12.4



    5.7



    14.7



    2.2



    19.8

































        U.S.

    15.0



    12.3



    11.1



    10.6



    5.5



    20.9



    (2.8)



    27.1

        International

    10.5



    0.3



    8.8



    19.1



    5.8



    9.6



    22.7



    15.4

     

    Worldwide Medical Devices sales increased 9.9 percent on a reported basis and 12.6 percent on an organic basis in the first quarter.

    Sales growth in the quarter was led by Diabetes Care, Structural Heart, Heart Failure and Electrophysiology.

    Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip®, Amplatzer® Amulet®, and AVEIR®.

    In Diabetes Care, sales of continuous glucose monitors were $1.7 billion and grew 18.3 percent on a reported basis and 21.6 percent on an organic basis.

    ABBOTT'S FINANCIAL GUIDANCE

    Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.

    Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.

    Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27.

    Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

    ABBOTT DECLARES 405th CONSECUTIVE QUARTERLY DIVIDEND

    On Feb. 21, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025.

    Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

    Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

    — Private Securities Litigation Reform Act of 1995 —

    A Caution Concerning Forward-Looking Statements

    Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    1.

    In the first quarter of 2025, total worldwide sales were $10.358 billion, total Diagnostics sales were $2.054 billion and COVID-19 testing-related sales were $84 million. In the first quarter of 2024, total worldwide sales were $9.964 billion, total Diagnostics sales were $2.214 billion and COVID-19 testing-related sales were $204 million. In the first quarter of 2025, the impact of COVID-19 testing-related sales on Abbott and total Diagnostics was a decrease of 1.4 percent and 5.4 percent, respectively. Organic sales, excluding COVID-19 testing-related sales, increased 8.3 percent for Abbott and 0.5 percent for total Diagnostics.

     

    Abbott Laboratories and Subsidiaries

    Condensed Consolidated Statement of Earnings

    First Quarter Ended March 31, 2025 and 2024

    (in millions, except per share data)

    (unaudited)









    1Q25



    1Q24



    % Change



    Net Sales

    $10,358



    $9,964



    4.0

















    Cost of products sold, excluding amortization expense

    4,468



    4,463



    0.1



    Amortization of intangible assets

    420



    472



    (11.0)



    Research and development

    716



    684



    4.6



    Selling, general, and administrative

    3,061



    2,959



    3.5



    Total Operating Cost and Expenses

    8,665



    8,578



    1.0

















    Operating Earnings

    1,693



    1,386



    22.1

















    Interest expense, net

    49



    61



    (18.6)



    Net foreign exchange (gain) loss

    (7)



    —



    n/m



    Other (income) expense, net

    (127)



    (111)



    14.9



    Earnings before taxes

    1,778



    1,436



    23.8



    Taxes on earnings

    453



    211



    n/m

    1)















    Net Earnings

    $1,325



    $1,225



    8.2

















    Net Earnings excluding Specified Items, as described below

    $1,919



    $1,729



    10.9

    2)















    Diluted Earnings per Common Share

    $0.76



    $0.70



    8.6

















    Diluted Earnings per Common Share,

    excluding Specified Items, as described below

    $1.09



    $0.98



    11.2

    2)















    Average Number of Common Shares Outstanding

    Plus Dilutive Common Stock Options

    1,747



    1,750







     

    NOTES:

    See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

    n/m = Percent change is not meaningful.

    See footnotes on the following section.



    1)

    2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.







    2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years.





    2)

    2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $594 million, or $0.33 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.







    2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $504 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

     

    Abbott Laboratories and Subsidiaries

    Non-GAAP Reconciliation of Financial Information

    First Quarter Ended March 31, 2025 and 2024

    (in millions, except per share data)

    (unaudited)





    1Q25



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $            420



    $          (420)



    $              —

    Gross Margin

    5,470



    448



    5,918

    R&D

    716



    (27)



    689

    SG&A

    3,061



    (10)



    3,051

    Other (income) expense, net

    (127)



    (35)



    (162)

    Earnings before taxes

    1,778



    520



    2,298

    Taxes on Earnings

    453



    (74)



    379

    Net Earnings

    1,325



    594



    1,919

    Diluted Earnings per Share

    $           0.76



    $           0.33



    $           1.09

     

    Specified items reflect intangible amortization expense of $420 million and other net expenses of $100 million associated with restructuring actions, costs associated with acquisitions, investment impairment charges and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.



    1Q24



    As

    Reported

    (GAAP)



    Specified

    Items



    As

    Adjusted













    Intangible Amortization

    $            472



    $          (472)



    $              —

    Gross Margin

    5,029



    518



    5,547

    R&D

    684



    (21)



    663

    SG&A

    2,959



    (34)



    2,925

    Other (income) expense, net

    (111)



    (26)



    (137)

    Earnings before taxes

    1,436



    599



    2,035

    Taxes on Earnings

    211



    95



    306

    Net Earnings

    1,225



    504



    1,729

    Diluted Earnings per Share

    $           0.70



    $           0.28



    $           0.98

     

    Specified items reflect intangible amortization expense of $472 million and other net expenses of $127 million associated with restructuring actions, costs associated with acquisitions, investment impairment charges and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

    A reconciliation of the first-quarter tax rates for 2025 and 2024 is shown below: 



    1Q25



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         1,778



    $            453



    25.5 %

    1)

    Specified items

    520



    (74)







    Excluding specified items

    $         2,298



    $            379



    16.5 %



















    1Q24



    ($ in millions)

    Pre-Tax

    Income



    Taxes on

    Earnings



    Tax

    Rate



    As reported (GAAP)

    $         1,436



    $            211



    14.7 %

    2)

    Specified items

    599



    95







    Excluding specified items

    $         2,035



    $            306



    15.0 %





    1)

    2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.





    2)

    2024 Taxes on Earnings includes the recognition of approximately $10 million of net tax expense as a result of the resolution of various tax positions related to prior years.

     

    Abbott Laboratories and Subsidiaries

    Non-GAAP Revenue Reconciliation

    First Quarter Ended March 31, 2025 and 2024

    ($ in millions)

    (unaudited)







    1Q25



    1Q24



    % Change vs. 1Q24





















    Non-GAAP





    Abbott

    Reported



    Abbott

    Reported

    Impact

    from

    business

    exit (a)

    Adjusted

    Revenue



    Reported



    Adjusted

    Organic

    Total Company



    10,358



    9,964

    (13)

    9,951



    4.0



    4.1

    6.9

    U.S.



    4,168



    3,846

    (13)

    3,833



    8.4



    8.8

    8.8

    Intl



    6,190



    6,118

    —

    6,118



    1.2



    1.2

    5.7

























    Total Nutrition



    2,146



    2,068

    (13)

    2,055



    3.8



    4.4

    6.8

    U.S.



    955



    878

    (13)

    865



    8.8



    10.4

    10.4

    Intl



    1,191



    1,190

    —

    1,190



    0.1



    0.1

    4.2

























    Adult Nutrition



    1,105



    1,059

    (13)

    1,046



    4.4



    5.8

    8.7

    U.S.



    367



    364

    (13)

    351



    1.1



    4.8

    4.8

    Intl



    738



    695

    —

    695



    6.1



    6.1

    10.6





    (a)

    Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    First Quarter Ended March 31, 2025

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                  —



    $                  26



    $                420



    $                    2



    $                448

    R&D

    (1)



    (16)



    —



    (10)



    (27)

    SG&A

    (3)



    (7)



    —



    —



    (10)

    Other (income) expense, net

    (24)



    —



    —



    (11)



    (35)

    Earnings before taxes

    $                  28



    $                  49



    $                420



    $                  23



    520

    Taxes on Earnings (d)

















    (74)

    Net Earnings

















    $                594

    Diluted Earnings per Share

















    $               0.33





    The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."



    a)

    Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses as well as a fair value adjustment to contingent consideration related to a business acquisition.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment impairment charges.





    d)

    Reflects the net tax benefit associated with the specified items. 2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

     

    Abbott Laboratories and Subsidiaries

    Details of Specified Items

    First Quarter Ended March 31, 2024

    (in millions, except per share data)

    (unaudited)





    Acquisition or

    Divestiture-

    related (a)



    Restructuring

    and Cost

    Reduction

    Initiatives (b)



    Intangible

    Amortization



    Other (c)



    Total

    Specifieds

    Gross Margin

    $                    1



    $                  42



    $                472



    $                    3



    $                518

    R&D

    (3)



    (2)



    —



    (16)



    (21)

    SG&A

    (14)



    (9)



    —



    (11)



    (34)

    Other (income) expense, net

    12



    —



    —



    (38)



    (26)

    Earnings before taxes

    $                    6



    $                  53



    $                472



    $                  68



    599

    Taxes on Earnings (d)

















    95

    Net Earnings

















    $                504

    Diluted Earnings per Share

















    $               0.28





    The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."



    a)

    Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.





    b)

    Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.





    c)

    Other includes various investment impairment charges and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.





    d)

    Reflects the net tax benefit associated with the specified items. 

     

    Cision View original content:https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-302430212.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    5/30/2023$112.00Overweight → Equal-Weight
    Morgan Stanley
    4/20/2023$125.00 → $127.00Overweight
    Barclays
    4/20/2023$107.00 → $103.00Underperform
    Wolfe Research
    More analyst ratings

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

      The test, run on Abbott's portable i-STAT® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutesThe test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025ABBOTT PARK, Ill., and IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and MotoAmerica, the premier motorcycle road racing series in North America, announced today that MotoAmerica is the first professional sports organization worldwide to use Abbott's groundbreaking blood test to help assess suspe

      5/1/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    SEC Filings

    See more
    • Abbott Laboratories filed SEC Form 8-K: Leadership Update

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      5/1/25 4:01:21 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abbott Laboratories

      10-Q - ABBOTT LABORATORIES (0000001800) (Filer)

      4/30/25 4:14:32 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Laboratories filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      4/28/25 4:10:13 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Abbott Labs with a new price target

      Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

      10/8/24 7:11:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abbott Labs with a new price target

      Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

      9/19/24 7:31:59 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Labs downgraded by Edward Jones

      Edward Jones downgraded Abbott Labs from Buy to Hold

      7/30/24 6:16:11 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

      For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

      10/24/23 3:52:17 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    See more

    $ABT
    Financials

    Live finance-specific insights

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

      First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

      4/16/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for First-Quarter Earnings

      ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi

      3/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/23 10:54:50 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/9/22 3:15:56 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blount Sally E. sold $337,116 worth of Common shares without par value (2,600 units at $129.66), decreasing direct ownership by 7% to 34,058 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      5/2/25 5:04:05 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Stratton John G was granted 1,635 units of Common shares without par value, increasing direct ownership by 9% to 19,033 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:30:29 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Starks Daniel J was granted 1,635 units of Common shares without par value, increasing direct ownership by 0.02% to 6,728,817 units (SEC Form 4)

      4 - ABBOTT LABORATORIES (0000001800) (Issuer)

      4/29/25 6:22:08 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care